- Scemblix (asciminib) Tablets
Date of Approval: October 29, 2021
Treatment for: Chronic Myelogenous Leukemia
Press Release | Approval History - Vuity (pilocarpine hydrochloride) Ophthalmic Solution
Date of Approval: October 28, 2021
Treatment for: Presbyopia
Press Release | Approval History - Susvimo (ranibizumab) Injection for Intravitreal Use via Ocular Implant
Date of Approval: October 25, 2021
Treatment for:
Press Release | Approval History - Xipere (triamcinolone acetonide) Injection
Date of Approval: October 22, 2021
Treatment for: Macular Edema, Uveitis
Press Release | Approval History - Zimhi (naloxone hydrochloride) Injection
Date of Approval: October 15, 2021
Treatment for: Opioid Overdose
Press Release | Approval History - Seglentis (celecoxib and tramadol hydrochloride) Tablets
Date of Approval: October 15, 2021
Treatment for: Pain
Press Release | Approval History - Tyrvaya (varenicline) Nasal Spray
Date of Approval: October 15, 2021
Treatment for: Dry Eye Disease
Press Release | Approval History - Rethymic (allogeneic processed thymus tissue-agdc) for Surgical Implantation
Date of Approval: October 8, 2021
Treatment for: Congenital Athymia
Press Release | Approval History - Tavneos (avacopan) Capsules
Date of Approval: October 7, 2021
Treatment for: ANCA-Associated Vasculitis
Press Release | Approval History
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00306932607174,00302841026182,alsfakia@gmail.com
Αναζήτηση αυτού του ιστολογίου
Πληροφορίες
Ετικέτες
Τετάρτη 3 Νοεμβρίου 2021
New Drug Approvals
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: Available online 25 July 2018 Source: Journal of Photochemistry and Photobiology B: Biology Author(s): Marco Ballestr...
-
Editorial AJR Reviewers: Heartfelt Thanks From the Editors and Staff Thomas H. Berquist 1 Share + Affiliation: Citation: American Journal...
-
Publication date: Available online 28 September 2017 Source: Actas Dermo-Sifiliográficas Author(s): F.J. Navarro-Triviño
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.